Our customers operate in the front lines of the biomedical sciences. To offer them the best possible service and to be able to respond to the latest developments it is important to have a sounding board within the different disciplines of Biomedical Sciences. Our Scientific Advisory Board, consisting of leading scientists, signals the developments and gives us solicited and unsolicited advice. This way we remain up-to-date and state-of-the-art in helping you with our services and innovative solutions to bring your research further.
Our Scientific Advisory Board consists of:
Prof. Dr. Alain de Bruin
Oncology, Veterinary Pathology / Affiliation: University of Utrecht
Alain de Bruin’s group is interested in the molecular mechanisms that control cell proliferation in normal cells and in cancer cells. The group wants to understand how E2F transcription factors mediate the appropriate control of the cell cycle entry and exit that is required for normal development and tumour suppression. Read more>>
Prof. Dr. Dorien Peters
Functional Genomics / Affiliation: Leiden University Medical Center
Focus of research is to get insight into the genetic, pathophysiologic and functional mechanisms of inherited disorders, most notably Polycystic Kidney Disease. The overall aim is the design of new therapeutic approaches. Different model systems are being used to perform an in-depth analysis of the molecular alterations, to identify new drug targets and test potential therapies.
Dr. Luuk Hawinkels
Cell-cell Interactions, Gastrointestinal Diseases / Affiliation: Leiden University Medical Center
The research laboratory Gastroenterology-Hepatology in the LUMC led by Dr. Hawinkels focusses on how interactions between different cell types (epithelial (tumour) cells, fibroblasts and immune cells) contribute to the pathogenesis and progression of gastrointestinal diseases. Our main focus in on inflammatory bowel disease (Ulcerative colitis and Crohn’s disease) and gastrointestinal cancers (oesophageal-, colorectal-, pancreatic cancer, hepatocellular carcinomas). Read more>> and Read more>>
Prof. Dr. Esther Wolfs
Imaging, Cancer, and Charcot-Marie-Tooth Disease / Affiliation: BIOMED research institute, Hasselt University
The research group of Esther Wolfs uses microscopic and non-invasive small-animal imaging (BLI, PET, MRI) in cancer and peripheral neuropathies such as Charcot-Marie-Tooth disease type 1A (CMT1A). Her research involves the use of pluripotent stem cells (iPSC and embryonic stem cells) and adult stem cells (dental pulp stem cells, mesenchymal stem cells) for disease modelling and for therapeutic applications.
The lab houses several in vitro assays (co-cultures, 3D cultures and myelination assays) and in vivo disease models (cancer models and CMT1A).
Prof. Dr. Leon de Windt
Cardiovascular Diseases / Affiliation: University Maastricht
De Windt’s laboratory is interested in cardiac gene regulatory mechanisms by transcription factors and microRNAs that control pathological cardiac remodelling, an early step towards heart failure. Read more>>
Marije Slingerland, MD PhD
Medical Oncology / Affiliation: Leiden University Medical Center
As clinician Marije Slingerland participates in, among other things, the multidisciplinary LUMC upper GI cancer team, the head and neck cancer team and the melanoma team. She is principal (and co-) investigator of international and national clinical trials in gastrointestinal cancer and in head and neck cancer. She has initiated and is the principal investigator of a study exploring immune factors related to the efficacy of immunotherapy in treated patients by performing an in-depth analysis of systemic and intratumoral immune parameters.
Prof. Dr. Jens Schwamborn
Neurodegenerative Diseases / Affiliation: University of Luxembourg
Recent findings show that Parkinson’s disease (PD) is a disorder not only characterised by a loss of dopaminergic neurons in the substantia nigra, but probably also has a strong neuro-developmental aspect. The aim of Schwamborn’s research is to understand, model and treat PD. Particularly, they are interested in elucidating how developmental processes contribute to the susceptibility to suffer from PD. Human stem cells, either neural stem cells or pluripotent stem cells, are in the centre of all of this research approaches. They use these cells to generate advanced in vitro disease models, including three-dimensional brain organoids (so called “mini-brains”), which shall help them to understand the cellular and molecular processes underlying disease onset and progression. By further developing these models, they will at least partially be able to replace animal experiments and to take an additional step in the direction of personalised medicine. Concerning the molecular processes they are particularly interested in linking the molecular function of PD-associated proteins with cell cycle progression, protein aggregation and mitochondrial / lysosomal function. Additionally to PD, they are also working on Battens disease / Neuronal Ceroid-Lipofuscinosis (NCL), which is a childhood neurodegenerative disease.